Corvus Pharmaceuticals (CRVS) Change in Acquisitions & Divestments (2015 - 2026)

Corvus Pharmaceuticals' Change in Acquisitions & Divestments history runs 12 years deep, the most recent figure standing at $17.0 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 41.67% year-over-year to $17.0 million in Q1 2026; TTM through Mar 2026 was $89.1 million, a 78.26% increase from a year earlier, with the FY2025 full-year figure at $84.1 million, up 97.34% from the prior year.
• Change in Acquisitions & Divestments eased to $17.0 million in Q1 2026 per CRVS's latest filing, from $24.3 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $28.5 million in Q3 2025 and bottomed at $810000.0 in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $15.4 million (2022), against an average of $14.7 million.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 90.08% in 2022 and surged 2088.27% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $15.4 million in 2022, then slumped by 40.85% to $9.1 million in 2023, then jumped by 56.73% to $14.3 million in 2024, then soared by 70.41% to $24.3 million in 2025, then tumbled by 30.18% to $17.0 million in 2026.
• Per Business Quant, the three latest CRVS Change in Acquisitions & Divestments figures stand at $17.0 million (Q1 2026), $24.3 million (Q4 2025), and $28.5 million (Q3 2025).